

# Curriculum Vitae – Melanie Janning, MD

---

## contact information

name: Melanie Janning, MD, MSc

address: Theodor-Kutzer Ufer 1-3, 68167 Mannheim, Germany

phone +49 (0)621 383 1755

mail: melanie.janning@medma.uni-heidelberg.de, melanie.janning@dkfz.de

## education:

2020 Board certification internal medicine, hematology and oncology; Hamburg, Germany

2017 M.D. (Dr. med), Philipps-University, Marburg, Germany

2008 MSc (Diplom) Human biology, Philipps-University, Marburg, Germany

2007 Medical Degree, Philipps-University, Marburg, Germany

## work experience:

since 08/2024 Head of Liquid Biopsy and Single Cell Technologies Group at the DKFZ-Hector Cancer Institute in Mannheim and the German Cancer Research Center (DKFZ) Heidelberg, Germany

since 08/2024 Deputy Head of Department of Personalized Oncology with section Lung Cancer at the University Hospital Mannheim, Germany

05/2020-07/2024 Attending Physician at the Department of Personalized Oncology with section Lung Cancer, University Hospital Mannheim, Germany

05/2020 – 07/2024 Junior Group Leader in Liquid Biopsy and single cell technologies at the DKFZ-Hector Cancer Institute -Mannheim and the Department of Personalized Medical Oncology, DKFZ, Heidelberg, Germany

2012-2020 Clinician Scientist at the group of Prof. Sonja Loges, Personalized Cancer Therapies, Department of Tumor Biology at the University Hospital, Hamburg-Eppendorf (UKE), Germany

2010-2020 Resident in Hematology and Oncology at the University Hospital, Hamburg-Eppendorf (UKE), Germany

2008-2010 Research Assistant at the Weatherall Institute of Molecular Medicine, Oxford University, England

## Fellowships / Prizes:

2024 Takeda Research Prize Oncology for “Diagnostic Leukapheresis Reveals Distinct Phenotypes of NSCLC Circulating Tumor Cells”

2023 ELBS – European Liquid Biopsy Society- Rita Zamarchi Young Investigator Award

2017-2022 Margarete Clemens Stiftung

2012 Hubertus-Wald Fellowship, University Cancer Center Hamburg, University Hospital, Hamburg-Eppendorf (UKE), Germany

2007 DAAD – German Academic Exchange Service – Fellowship for Master Theses abroad

## Clinical Trials:

2020 - Principle Investigator in 7 trials (Phase 2 & 3, Register): PM1183-C-008-21 LAGOON (SCLC), GS-US-577-6153-Evoke-01 (NSCLC), INCB 54828-210 FIGHT-210 (NSCLC), M18-868-TeliMET (NSCLC), BREAK B5-BM (NSCLC), AIO-TRK-0315-CRSIP (NSCLC), MK-3475-D45-Evoke-03 (NSCLC)

2012 - Sub-Investigator in 26 trials (Register, Phase 1-3): AIO-BHNO-CONNECT (Register) Impower101-GO29527 (NSCLC), GMALL-MOLACTI-BLINA (ALL), CLL 2P (CLL), BRIGHT-AML 1019, Abbvie MI6-043, AMLSG 19-13/ARO-007, AML2002-Janssen,

AMLSG 23-14, BI 1315.2, Bayer 19036, Quantum-First, AMLSG 15-10, AMLSG 17-10, AMLSG 16-10, AMLSG 11-08, AML CALGB Ratify, AML-W029519, AMLSG 20-13, AMLSG-21-13, Abbvie M14-387, BI 1230.14, AML-GO, AMLS-SG Register, APOLLO, BGBC003 alle AML

### Teaching:

- 2020 - Medical students at the Medical Faculty Mannheim of the University Heidelberg, Germany
- 2018 - Supervision of 3 PhD-, 4 MD-, and 3 Master students
- 2018-2020 Mentor for Medical Students within the Excellency Program for MD Students of the University Hospital, Hamburg-Eppendorf (UKE), Germany
- 2016 -2020 Hematology course for nurses within the Oncology Nurse Speciality Training Program at the UKE-Bildungsakademie, Hamburg, Germany
- 2010-2020 Medical students at the Medical Faculty of the University Hospital Hamburg-Eppendorf, Germany

### Journal reviews:

Ad hoc review OncoImmunology, Translational Lung Cancer Research, Molecular Oncology, Molecules, Cancers, European Journal of Cancer

International Association for the Study of Lung Cancer (IASLC), Swiss Cancer Research, Deutsche Krebshilfe (DKH), Polish National Science Center, Deutsche Forschungsgemeinschaft (DFG)

### Interests:

Oncology, Thoracic Oncology, Liquid Biopsies, Circulating Tumor Cells, Resistance, Immune Therapies, Targeted Treatments, Rare variants of known molecular driver, Biomarker,

### Membership:

Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)  
European Society of Medical Oncology (ESMO)  
American Society of Clinical Oncology (ASCO)  
Deutsche Krebsgesellschaft (DKG)  
Arbeitsgemeinschaft Internistische Onkologie (AIO)  
International Association for the Study of Lung Cancer (IASLC)  
European Liquid Biopsy Society (ELBS)  
International Society of Liquid Biopsy (ISLB)

### Selected publications

1. Rieckmann, L. M.\*, Spohn, M., Ruff, L., Agorku, D., Becker, L., Borchers, A., Krause, J., O'Reilly, R., Hille, J., Velthaus-Rusik, J. L., Beumer, N., Gunther, A., Willnow, L., Imbusch, C. D., Iglauer, P., Simon, R., Franzenburg, S., Winter, H., Thomas, M., Bokemeyer, C., Gagliani, N., Krebs, C. F., Sprick, M., Hardt, O., Riethdorf, S., Trumpp, A., Stoecklein, N. H., Peine, S., Rosenstiel, P., Pantel, K., Loges, S.\*, and **Janning, M.\*** (2024) Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells. *Mol Cancer* **23**, 93
2. Bischoff, P., Reck, M., Overbeck, T., Christopoulos, P., Rittmeyer, A., Luders, H., Kollmeier, J., Kulhavy, J., Kemper, M., Reinmuth, N., Roper, J., **Janning, M.**, Sommer, L., Aguinarte, L., Koch, M., Wiesweg, M., Wessler, C., Waller, C. F., Kauffmann-Guerrero, D., Stenzinger, A., Stephan-Falkenau, S., Trautmann, M., Lassmann, S., Tiemann, M., Klauschen, F., Sebastian, M., Griesinger, F., Wolf, J., Loges, S., Frost, N., and National Network Genomic Medicine Lung Cancer Collaborator, G. (2024) Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1-High (>=50%) NSCLC in the German National Network Genomic Medicine Lung Cancer. *J Thorac Oncol* **19**, 803-817
3. Leest, P. V.\*, **Janning, M.\***, Rifaela, N., Azpurua, M. L. A., Kropidowski, J., Loges, S., Lozano, N., Sartori, A., Irwin, D., Lamy, P. J., Hiltermann, T. J. N., Groen, H. J. M., Pantel, K., Kempen, L. C. V., Wikman, H., and Schuurin, E. (2023) Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients. *Int J Mol Sci* **24**

4. **Janning, M.**, Suptitz, J., Albers-Leischner, C., Delpy, P., Tufman, A., Velthaus-Rusik, J. L., Reck, M., Jung, A., Kauffmann-Guerrero, D., Bonzheim, I., Brandlein, S., Hummel, H. D., Wiesweg, M., Schildhaus, H. U., Stratmann, J. A., Sebastian, M., Alt, J., Buth, J., Esposito, I., Berger, J., Togel, L., Saalfeld, F. C., Wermke, M., Merkelbach-Bruse, S., Hillmer, A. M., Klauschen, F., Bokemeyer, C., Buettner, R., Wolf, J., Loges, S., and National Network Genomic Medicine Lung, C. (2022) Treatment outcome of atypical EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM). *Ann Oncol* **33**, 602-615
5. Christopoulos, P., Kluck, K., Kirchner, M., Luders, H., Roeper, J., Falkenstern-Ge, R. F., Szewczyk, M., Sticht, F., Saalfeld, F. C., Wesseler, C., Hackanson, B., Dintner, S., Faehling, M., Kuon, J., **Janning, M.**, Kauffmann-Guerrero, D., Kazdal, D., Kurz, S., Eichhorn, F., Bozorgmehr, F., Shah, R., Tufman, A., Wermke, M., Loges, S., Brueckl, W. M., Schulz, C., Misch, D., Frost, N., Kollmeier, J., Reck, M., Griesinger, F., Grohe, C., Hong, J. L., Lin, H. M., Budczies, J., Stenzinger, A., and Thomas, M. (2022) The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions. *Eur J Cancer* **170**, 106-118
6. Boch, T., Frost, N., Sommer, L., Overbeck, T. R., Michaeli, C. T., Szuszies, C. J., Rieckmann, L. M., Beumer, N., Imbusch, C. D., Winter, H., Thomas, M., Roeper, J., **Janning, M.**, Griesinger, F., Wermke, M., and Loges, S. (2022) Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery. *Lung Cancer* **164**, 46-51
7. Zhao, L., Giannou, A. D., Xu, Y., Shiri, A. M., Liebold, I., Steglich, B., Bedke, T., Zhang, T., Lucke, J., Scognamiglio, P., Kempfski, J., Woestemeier, A., Chen, J., Agaloti, T., Zazara, D. E., Lindner, D., **Janning, M.**, Hennigs, J. K., Jagirdar, R. M., Kotsiou, O. S., Zarogiannis, S. G., Kobayashi, Y., Izbicki, J. R., Ghosh, S., Rothlin, C. V., Bosurgi, L., Huber, S., and Gagliani, N. (2021) Efferocytosis fuels malignant pleural effusion through TIMP1. *Sci Adv* **7**
8. Belloum Y\*, **Janning M\***, Mohme M, Simon R, Kropidowski J, Sartori A, Irwin D, Westphal M, Lamszus K, Loges S, Riethdorf S, Pantel K\*, Wikman H\*. Discovery of Targetable Genetic Alterations in NSCLC Patients with Different Metastatic Patterns Using a MassARRAY-Based Circulating Tumor DNA Assay. *Cells* 2020, 9(11) (\*equal contribution).
9. **Janning M\***, Kobus F\*, Babayan A, Wikman H, Velthaus JL, Bergmann S, Schatz S, Falk M, Berger LA, Bottcher LM, Pasler S, Gorges TM, O'Flaherty L, Hille C, Joosse SA, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S. Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors. *Cancers (Basel)* 2019; 11. (\*equal contribution).
10. Berger LA, **Janning M**, Velthaus JL, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S. Identification of a High-Level MET Amplification in CTCs and cTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. *J Thorac Oncol* 2018; 13: e243-e246.

Mannheim, 10.03.2026

Dr. med. Melanie Janning